CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed
Drug / intervention
THALIDOMIDE +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00358020
NCT00358020Phase 2Completed
CompareCT.gov

A Phase II, Multi-Center, Open Label Study Of Melphalan, Prednisone, Thalidomide And Bortezomib In Advanced And Refractory Multiple Myeloma Patients

University of Turin, Italy·interventional·Posted Jul 28, 2006·Updated Dec 4, 2006

In Brief

A Phase 2 clinical trial evaluating THALIDOMIDE and BORTEZOMIB for Multiple Myeloma. Completed, across 7 sites.

Detailed Summary

The purpose of this study is to evaluate the safety and the efficacy of the association of Melphalan/Prednisone/Thalidomide/VELCADE (MPTV) as salvage treatment in advanced and refractory myeloma patients. This association might further increase the response rate achieved by the standard oral MP regimen.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Myeloma
CountriesItaly
Collaborators--

Timeline

Phase 2CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 28, 2006
Enrollment StartNov 1, 2004
Study CompletionDec 1, 2008
TodayJul 2, 2026
Posted 19.9 years ago

Interventions

THALIDOMIDEdrug

BORTEZOMIBdrug